Insulin Costs and Coverage in Medicare Part D June 4, 2020 Issue Brief In light of heightened attention to insulin and the Trump Administration’s new Part D model to address out-of-pocket costs for insulin for Medicare beneficiaries, we analyzed out-of-pocket spending on insulin by beneficiaries enrolled in Part D drug plans, variation in Part D plan formulary coverage and tier placement of insulin products, and trends in prices for insulin.
State Medicaid Management of Prescription Drugs for HIV Treatment and Prevention June 4, 2020 Issue Brief This data note, primarily based on a survey of state Medicaid pharmacies, reviews cost-containment policies and protections as they relate to antiretrovirals for treatment and prevention of HIV.
JAMA Forum: Trump vs Biden on Health Care September 3, 2020 Perspective In this September 2020 post for The JAMA Health Forum, Larry Levitt highlights differences in the records and policy plans of President Donald Trump and former Vice President Joe Biden on key health care issues.
Most People Are Unlikely to See Drug Cost Savings From President Trump’s “Most Favored Nation” Proposal August 27, 2020 Blog This policy watch examines the likely impact of an executive order signed by President Trump in July 2020 related to prescription drugs, which would use lower international drug prices to set prices for a limited set of drugs in the U.S.
Amid the Coronavirus Crisis, President Trump and Democratic Nominee Joe Biden Offer Widely Different Views on Health Care August 20, 2020 News Release President Trump and Democratic nominee Joe Biden hold widely divergent views on health issues, with the president’s record and response to the coronavirus pandemic likely to play a central role in November’s elections. A new KFF side-by-side comparison examines President Trump’s record and former Vice President Biden’s positions across a…
Analysis Finds 14 Million Medicare Part D and Large Employer Plan Enrollees Used Mail-Order Pharmacies Pre-Pandemic, Top Drugs Filled Were to Treat Chronic Conditions August 20, 2020 News Release With questions being raised about potential delays in U.S. Postal Service delivery, a new KFF data note estimates 14 million enrollees in Medicare Part D and large employer plans relied on mail-order pharmacies for at least one prescription in 2018, with a total of over 170 million prescriptions fulfilled. The…
Mail Delays Could Affect Mail-Order Prescriptions for Millions of Medicare Part D and Large Employer Plan Enrollees August 20, 2020 Issue Brief Potential changes in mail service delivery could be a concern for people who receive prescription drugs from mail-order pharmacies. To understand who may be most affected by delays in the delivery of prescription drugs, we analyzed use of mail order in Medicare Part D and large group employer plans, and identified the therapeutic classes and specific drugs with the highest volume of fills by mail-order pharmacies in each market.
Health Affairs Article: Medicare Part D Plans Rarely Cover Brand-Name Drugs When Generics Are Available August 10, 2020 Issue Brief In an article in Health Affairs, KFF’s Juliette Cubanski, Sarah True and Tricia Neuman, and several other co-authors, explore how often brand-name drugs receive favorable formulary inclusion relative to generics in the Medicare Part D program’s prescription drug plans.
Medicaid Pharmacy Benefits State Fact Sheets August 6, 2020 Interactive These state fact sheets offer a snapshot of the administration and delivery of Medicaid pharmacy benefits in each state.
